Articles tagged with Immunotherapy
The ECOG-ACRIN Cancer Research Group has completed enrollment of 600 patients in the phase 2/3 trial EA6141, evaluating dual checkpoint blockade with nivolumab and ipilimumab plus sargramostim for unresectable stage 3 or 4 melanoma. The trial aims to assess overall survival, progression-free survival, and treatment tolerability.
Researchers engineered supercharged T cells that can recognize and kill prostate cancer cells more effectively. By fine-tuning how they physically interact with tumor cells, the T cells form a stronger bond, allowing them to deliver a targeted immune response without damaging healthy tissue.
Researchers at UCLA have developed a novel immunotherapy that uses CAR-NKT cell therapy to fight endometrial cancer. The therapy achieved complete tumor elimination and prolonged survival in mouse models, outperforming conventional CAR-T cell therapies.
The Sylvester Cancer Tip Sheet for March 2026 highlights the importance of genetic testing for cancer risk assessment. Researchers have made significant progress in developing new treatments, including mRNA-based immunotherapy for colorectal and pancreatic cancers. Additionally, the Dolphins Cancer Challenge has surpassed $100 million ...
Researchers at Arc Institute and Stanford University found that ketone body β-hydroxybutyrate strengthens CAR T cell fitness and antitumor activity. BHB supplementation improves CAR T cell expansion and tumor killing in mice, mirroring the effects of a ketogenic diet.
Researchers at UC San Diego discover a new way to re-educate the immune system to attack ovarian cancer tumors by blocking protein FAK. The study offers hope for developing better treatments by turning the tumor environment from immune-suppressing to immune-activating.
The James P. Allison Institute at UT MD Anderson Cancer Center appoints Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon to advance immunotherapy research. These experts bring expertise in immune therapy resistance, cancer vaccines, bioengineering, tumor evolution, and drug development.
Researchers developed a new immunotherapy strategy by pairing next-generation therapy with standard hormone therapy before surgery, reducing Treg levels inside tumors and improving patient outcomes. The study provides clinical evidence for the effectiveness of engineered anti-CTLA-4 therapies in early-stage prostate cancer treatment.
Researchers developed mRNA-encoded nanobodies to combat colorectal cancer, offering new hope for patients resistant to conventional immunotherapies. The treatment demonstrated superior efficacy against sporadic and colitis-associated colorectal cancer.
Researchers have engineered a novel CAR-T cell that can be switched off on demand using a cancer drug, offering improved safety and efficacy. The new system, known as DROP-CAR-T, uses a clinically approved drug to disrupt tumor cell binding, preserving the cells for continued treatment.
A new UCLA study found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer. The combination treatment helped patients live long enough to reach surgery, shrank tumors, and produced encouraging survival outcomes.
Researchers have engineered Listeria bacteria to stimulate the body's innate immune system and eliminate cancer cells. The therapy, which boosts gamma delta T cells, shows promise in treating children with leukemia and preventing graft-versus-host disease.
Researchers have developed a breakthrough technique to transform a patient's own T cells into soldiers trained to recognize and kill cancer cells, benefiting tens of thousands of individuals with blood cancers. The approach is now being explored for solid tumors and other diseases.
Researchers developed a PD-L1-binding antigen presenter that redirects antiviral antibodies to target cancer cells, transforming virus-specific immune memory into precision anti-cancer weapons. This strategy has significant potential for treating hard-to-treat cancers and represents a lower-cost, safer avenue for tumor immunotherapy.
Researchers at the University of Illinois have found that the ABCA1 protein plays a crucial role in directing how myeloid immune cells, particularly macrophages, behave. When ABCA1 is expressed, these cells become better at fighting cancer and supporting T cell function.
Researchers at Salk Institute uncover two transcription factors, ZSCAN20 and JDP2, that determine T cell fate. Turning off these genes reverses T cell exhaustion and restores their ability to kill tumors without losing immune memory. The study challenges the long-standing belief of inevitable immune exhaustion.
A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to treat multiple solid tumors. The 4-1BB-containing CAR design emerged as superior, demonstrating strongest anti-tumor activity and persistence.
Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster and cheaper than before. This new technology enables researchers to assess which CAR T variants are most promising much more quickly, leading to safer and more targeted cancer treatments.
Dr. George Coukos, a leading authority on tumor immunology and cellular immunotherapy, joins Weill Cornell Medicine to lead the Ludwig Laboratory for Cell Therapy.
A new clinical trial shows that treating desmoplastic melanoma with immunotherapy before surgery dramatically shrinks or eliminates tumors, improving quality of life for patients. The study found that 71% of patients had no detectable cancer remaining at the time of surgery.
A novel antibody-based therapy has been shown to reduce plaque in the arteries of mice, eliminating harmful immune cells that drive inflammation and unstable plaque formation. This immunotherapy could complement traditional methods and help patients with advanced coronary artery disease.
Lipid droplets regulate diverse cellular processes in cancer, including membrane biosynthesis and metabolic homeostasis. Targeting lipid metabolism may disrupt tumor survival and counteract immune cell-mediated protumorigenic effects.
Researchers at Salk Institute debut an epigenetic catalog that shows genetic inheritance and life experiences have distinct effects on various types of immune cells, shedding light on individual differences in immune responses and potential new personalized therapeutics.
A Mount Sinai study found that antibody-producing immune cells called IgG1 plasma cells help patients respond to PD-1 immune checkpoint inhibitors, which have transformed cancer care. The researchers identified IgG1 plasma cells as a critical factor in determining clinical outcomes.
The cGAS-STING pathway plays a crucial role in detecting cellular DNA, triggering type I interferons and cytokines, and modulating immune responses. Its therapeutic potential is being explored in cancer and various diseases, with promising preclinical evidence suggesting its potential as a target for next-generation immunotherapies.
Researchers propose a new conceptual framework for neutrophils, highlighting their dynamic and adaptable nature. The study reveals neutrophils' functional diversification and immunological memory capabilities, opening avenues for innovative therapeutic strategies.
A study from Flinders University found that patients with progressive disease, which describes the way cancer grows, have varying survival rates depending on whether their existing tumours re-grow or new ones appear. Understanding this progression can help doctors make better decisions about future treatment strategies.
Researchers discovered that CHD1 and MAP3K7 gene deletion improves tumor vulnerability to immunotherapy. This finding suggests new biomarkers for predicting patient response and opening up personalized cancer care. The study sheds light on why some patients are more or less likely to respond to certain types of cancer treatments.
Researchers at the University of Florida have discovered a small compound produced by gut bacteria that doubles the response to lung cancer immunotherapy treatment in mice. The findings could lead to a new combination therapy that boosts patient responsiveness by 50% without adding invasive treatments.
Researchers have created a library of over 400 immune-related factors to reprogram rare immune cell populations. This technique allows for the systematic discovery of 'recipes' for specific immune cells, offering hope for unresponsive patients and advancing immunotherapy.
A team at Texas Biomedical Research Institute found that even with effective treatments for TB and HIV, the immune system remains seriously out-of-whack following treatment. The study suggests that host-directed therapies specifically targeting the immune system could potentially restore lung immune system functionality.
A new blood test has been developed to predict which patients with lung cancer will benefit from the newly approved immunotherapy drug tarlatamab. The test, based on circulating tumor cells, correctly identified 85% of patients who responded to the drug and 100% of those who did not.
A Phase I study led by Timothy Yap demonstrates the potential of linavonkibart to target and prevent activation of transforming growth factor-beta 1 (TGFβ1), overcoming treatment resistance in multiple cancers. The trial showed manageable safety profiles and objective responses in heavily pre-treated patients, suggesting a promising ne...
Researchers have identified a new class of molecules that specifically degrade the cancer-promoting enzyme IDO1, offering a potential solution to enhance checkpoint-based immunotherapy. These IDO1 degraders may overcome limitations of previous inhibitors and open new avenues for treating various types of cancers.
A new study suggests that durvalumab may offer a promising treatment option for limited-stage small cell lung cancer patients, extending overall and progression-free survival. However, the therapy's high cost poses significant challenges to sustainability and access in the real-world setting.
Researchers at MD Anderson have made significant advancements in cancer treatment, demonstrating the effectiveness of immunotherapy before and after surgery in improving lung cancer patient outcomes. Additionally, a new study shows promise in using CAR T cell therapy to treat large B-cell lymphoma, reducing relapse rates.
Melanie Rutkowski's pioneering research may lead to novel immunotherapy treatments for ovarian cancer by understanding how faulty cellular signaling interacts with the microbiome. The grant aims to enhance immune system's ability to kill cancer cells and improve patient outcomes.
Researchers discovered that certain antibodies employ unusual tactics to block bacterial adhesion, including creating molecular wedges and conformational traps. These mechanisms could lead to the development of immune therapies targeting glycan-binding cell-attachment proteins produced by bacteria causing urinary tract infections.
Researchers discover breast cancer cells hijack the immune system's alarm pathway, inducing chronic pro-tumor inflammation. This shift creates a vulnerability that can be targeted by existing immunotherapies.
A new study found that a small dose of peanut oral immunotherapy can help children with their peanut allergy and reduce the risk of severe reactions from accidental exposures. Children receiving the low-dose treatment experienced significant increases in their allergic reaction threshold to peanuts.
Recent advances in immunotherapy have transformed multiple myeloma treatment, offering durable survival benefits. Emerging targets such as regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages are being explored to enhance treatment efficacy.
Researchers at MD Anderson Cancer Center have found that inhibiting GFER, a mitochondrial enzyme, in combination with immune checkpoint blockade improves antitumor response in preclinical models. This two-pronged approach holds promise for patients with pancreatic cancer.
Researchers at EPFL have developed two bioengineering approaches that exploit extracellular vesicles to train dendritic cells to identify cancer cells without the need for tumor material. The approaches, published in Nature Communications and Science Translational Medicine, show promising results in enhancing cancer immunotherapy.
Researchers at Rockefeller University discovered that the T cell receptor springs open when activated by an antigen, contrary to previous studies. This finding could lead to next-generation treatments for a broader group of cancer patients.
A large-scale study identified risk factors and clinical features of ICI-ITP, a rare but serious complication of anti-cancer immunotherapy. The study found that patients with ICI-ITP tend to have lower platelet counts at the start of treatment, experience additional immune-related adverse events, and have a higher risk of death.
A study published in Biological Psychiatry identifies a distinct immuno-inflammatory biomarker in the brain linked to immune system dysfunction and poorer response to standard treatments. The findings provide potential value for clinical prediction and precision therapies.
Researchers at Cold Spring Harbor Laboratory have devised a new approach to stimulate cell growth and repair in the intestine using CAR T-cell therapy. This therapy has shown promising results in improving gut health in both young and old mice, with significant reductions in inflammation and improved nutrient absorption.
A new Mayo Clinic study found that an off-the-shelf dual-antibody therapy generates deep and durable responses in extramedullary multiple myeloma. In a trial of 90 patients, 79% responded to treatment, with nearly two-thirds maintaining disease control at one year.
Insilico Medicine's Chemistry42 platform enables the efficient discovery of a potent, oral CBLB inhibitor with low toxicity risks and favorable ADME/PK profiles. The compound demonstrates strong in vitro activity and improved metabolic stability in mouse, rat, and dog models.
A precision medicine-based approach tailors treatment to each patient's unique immune status, improving disease severity and reducing organ failure. The study reveals a significant improvement in clinical outcomes for patients with specific types of sepsis.
Researchers found that patients who received immunochemotherapy before 3:00 pm experienced significantly longer progression-free survival and overall survival compared to those treated later. Earlier administration of immunotherapy was also associated with lower risks of cancer progression and death.
A new treatment using genome-edited immune cells has shown promising results in helping children and adults fight a rare form of blood cancer called T-cell acute lymphoblastic leukaemia (T-ALL). The gene therapy, known as BE-CAR7, uses base-editing to modify T-cells and destroy cancerous cells.
A new study by researchers at Karolinska Institutet found that lower doses of approved immunotherapy drugs can give better results against tumours, while reducing side effects. The regimen with the lower dose of ipilimumab was more effective, with a higher proportion of patients responding to treatment and longer overall survival.
A new combination therapy approach enabled seven out of ten participants to keep the virus at low levels for many months after going off antiretroviral therapy. The results suggest a possible cure for HIV and offer a proof of concept that this approach could work.
A new protocol for Treg expansion uses targeted immunotherapy to reduce transplant complications, boosting survival rates while preserving anti-cancer immunity. The protocol, led by Robert Levy, uses TL1A-Ig fusion protein and low-dose IL-2 to stimulate specific receptors on Tregs, promoting a safer environment for stem cell transplants.
Researchers discovered P. angustum selectively targets colorectal cancer, inducing direct tumor lysis and robust immune activation. The therapy promotes intratumoral infiltration of immune cells and enhances production of inflammatory cytokines, significantly prolonging survival in treated mice.
Researchers at UC Santa Barbara propose a cyst-targeted therapy using monoclonal antibodies to interrupt the runaway growth of fluid-filled sacs in polycystic kidney disease. The treatment, targeting a driver of cyst progression, shows promise in slowing or reversing the disease with minimal side effects.
Researchers have identified a protein complex that drives T cell exhaustion in tumors and show that disrupting it can revive exhausted anti-tumor CTLs. The study's findings offer new hope for improving the efficacy of cancer immunotherapy.
Researchers have presented a comprehensive review on synergistic ferroptosis–immunotherapy nanoplatforms to overcome TME resistance and enhance antitumor immunity. The work offers a systematic roadmap for integrating ferroptosis induction with immunotherapy.
Researchers at Chiba University have developed a nasal therapeutic vaccine targeting E7 oncoprotein, which is produced by high-risk strains of HPV associated with cervical cancer. The vaccine triggers an immune response in the cervical mucosa, providing local protection against pathogens and foreign particles.